stars 1 stars 2 stars 3

We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 30 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, in late 2005, as Supernus Pharmaceuticals Inc. We market our products in the United States through our own specialty sales force and seek strategic collaborations with other pharmaceutical companies to license our products outside the United States. We market Qelbree® (viloxazine extended-release) for the treatment of attention deficit/hyperactivity disorder (ADHD) in children ages 6 to 17. Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD), Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. We are also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD in adults, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.

View Top Employees from Supernus Pharmaceuticals, Inc.
Ticker SUPN
Revenue $392 million
Funding $80 million
Employees 688 (688 on RocketReach)
Founded 2005
Address 9715 Key West Ave, Rockville, Maryland 20850, US
Phone (301) 838-2500
Fax (301) 424-1364
JavaScript, HTML, Twitter +39 more (view full list)
Category Pharmaceutical Manufacturing, Drug Manufacturing & Research, Biotechnology, Drug Discovery, Pharmaceuticals, Science and Engineering, Healthcare, Health Care, Pharmaceutical
Web Rank 2 Million
Keywords supernus pharmaceuticals, supernus, supernus pharmaceuticals inc, supernus careers, spn 812
SIC 28, 283
NAICS 3254, 32, 32541, 541, 325, 54199, 5419, 54

Supernus Pharmaceuticals, Inc. Questions

The Supernus Pharmaceuticals, Inc. annual revenue was $392 million in 2023.

Jack Khattar is the Chairman, Board of Directors of Supernus Pharmaceuticals, Inc..

688 people are employed at Supernus Pharmaceuticals, Inc..

Supernus Pharmaceuticals, Inc. is based in Rockville, Maryland.

The NAICS codes for Supernus Pharmaceuticals, Inc. are [3254, 32, 32541, 541, 325, 54199, 5419, 54].

The SIC codes for Supernus Pharmaceuticals, Inc. are [28, 283].

The most common Supernus Pharmaceuticals, Inc. email format is [first_initial][last] (ex., which is being used by 92.9% of Supernus Pharmaceuticals, Inc. work email addresses.

Other common Supernus Pharmaceuticals, Inc. email patterns are [first].[last] (ex. and [last] (ex. In all, Supernus Pharmaceuticals, Inc. uses 3 work email formats.

Supernus Pharmaceuticals, Inc. Email Formats and Examples

Email Format Example Percentage

Lorem ipsum dolor sit amet consectetur adipisicing elit.

Lorem ipsum dolor sit amet

How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 5 free lookups / month.
Search over 700 million verified professionals across 35 million companies.
Get Contact Info
Get contact details including emails and phone numbers (business & personal).
G2Crowd Trusted
300K+ Plugin Users